Ralph R. Weichselbaum, MD, of the University of Chicago Cancer Research Center, explores the question of whether radiotherapy is the principal curative treatment with immunotherapy or activates immunotherapy. He also discussed how to improve the interaction of these treatments, perhaps with vaccination, transfer of genetically engineered T cells, or checkpoint inhibitors (Session ED37).
Elizabeth H. Stover, MD, PhD, of Dana-Farber Cancer Institute, discusses an analysis of genomic alterations in patients with relapsed ovarian cancer who were treated with niv...
Antoni Ribas, MD, PhD, of the University of California, Los Angeles, Jonsson Comprehensive Cancer Center, summarizes a special panel discussion on ways to eliminate cancer he...
Kala Visvanathan, MD, of Johns Hopkins Bloomberg School of Public Health, discusses her analysis of data from more than 10,000 women with ovarian cancer. The results suggest ...
Antoni Ribas, MD, PhD, of the University of California, Los Angeles, Jonsson Comprehensive Cancer Center, summarizes the opening plenary session that addressed epigenetics and early detection...
Stacey A. Fedewa, PhD, of the American Cancer Society, discusses the increasing incidence rates of colorectal, breast, kidney, thyroid, uterine corpus, and cervical disease i...